# BioCardia, Inc.: financial statements, quarterly

BCDA · Nasdaq · CIK 925741 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/bcda.md) · [Financials](/companies/bcda/financials.md) · [Filings](/companies/bcda/filings.md) · [Insiders](/companies/bcda/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/bcda/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [357](/filings/0001437749-24-034896.md) | [13.0 d](/filings/0001437749-25-009397.md) | [55.0](/filings/0001437749-25-016831.md) | [3.0](/filings/0001437749-25-032197.md) | [0.0](/filings/0001437749-25-034437.md) | [0.0 d](/filings/0001437749-26-009587.md) | [0.0](/filings/0001437749-25-016831.md) | [0.0](/filings/0001437749-25-032197.md) | [0.0](/filings/0001437749-25-034437.md) | [0.0 d](/filings/0001437749-26-009587.md) | not reported | not reported |
| Cost of revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $k | [1,872](/filings/0001437749-24-034896.md) | [1,156 d](/filings/0001437749-25-009397.md) | [1,241](/filings/0001437749-25-016831.md) | [800](/filings/0001437749-25-032197.md) | [931](/filings/0001437749-25-034437.md) | [1,415 d](/filings/0001437749-26-009587.md) | [1,530](/filings/0001437749-26-017221.md) | [1,368](/filings/0001437749-26-027315.md) | [936](/filings/0001437749-25-034437.md) | [1,128 d](/filings/0001437749-26-009587.md) | [1,235](/filings/0001437749-26-017221.md) | [893](/filings/0001437749-26-027315.md) |
| Selling, general and administrative | $k | [1,083](/filings/0001437749-24-034896.md) | [941 d](/filings/0001437749-25-009397.md) | [1,089](/filings/0001437749-25-016831.md) | [852](/filings/0001437749-25-032197.md) | [825](/filings/0001437749-25-034437.md) | [906 d](/filings/0001437749-26-009587.md) | [1,196](/filings/0001437749-26-017221.md) | [683](/filings/0001437749-26-027315.md) | [552](/filings/0001437749-25-034437.md) | [885 d](/filings/0001437749-26-009587.md) | [1,031](/filings/0001437749-26-017221.md) | [730](/filings/0001437749-26-027315.md) |
| Operating income | $k | [(2,598)](/filings/0001437749-24-034896.md) | [(2,084) d](/filings/0001437749-25-009397.md) | [(2,275)](/filings/0001437749-25-016831.md) | [(1,649)](/filings/0001437749-25-032197.md) | [(1,756)](/filings/0001437749-25-034437.md) | [(2,321) d](/filings/0001437749-26-009587.md) | [(2,726)](/filings/0001437749-26-017221.md) | [(2,051)](/filings/0001437749-26-027315.md) | [(1,488)](/filings/0001437749-25-034437.md) | [(2,013) d](/filings/0001437749-26-009587.md) | [(2,266)](/filings/0001437749-26-017221.md) | [(1,623)](/filings/0001437749-26-027315.md) |
| Interest expense | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $k | [0.0](/filings/0001437749-24-034896.md) | [0.0 d](/filings/0001437749-25-009397.md) | [0.0](/filings/0001437749-25-016831.md) | [0.0](/filings/0001437749-25-032197.md) | [0.0](/filings/0001437749-25-034437.md) | [0.0 d](/filings/0001437749-26-009587.md) | [0.0](/filings/0001437749-26-017221.md) | [0.0](/filings/0001437749-26-027315.md) | [0.0](/filings/0001437749-25-034437.md) | [0.0 d](/filings/0001437749-26-009587.md) | [0.0](/filings/0001437749-26-017221.md) | [0.0](/filings/0001437749-26-027315.md) |
| Net income | $k | [(2,574)](/filings/0001437749-24-034896.md) | [(2,072) d](/filings/0001437749-25-009397.md) | [(2,267)](/filings/0001437749-25-034437.md) | [(1,646)](/filings/0001437749-25-034437.md) | [(1,737)](/filings/0001437749-25-034437.md) | [(2,296) d](/filings/0001437749-26-009587.md) | [(2,712)](/filings/0001437749-26-027315.md) | [(2,049)](/filings/0001437749-26-027315.md) | [(1,483)](/filings/0001437749-25-034437.md) | [(1,984) d](/filings/0001437749-26-009587.md) | [(2,259)](/filings/0001437749-26-027315.md) | [(1,613)](/filings/0001437749-26-027315.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | [(0.59)](/filings/0001437749-26-017221.md) | [(0.40)](/filings/0001437749-26-027315.md) | not reported | not reported | [(0.21)](/filings/0001437749-26-017221.md) | not reported |
| Basic EPS | $ per share | [(1.79)](/filings/0001437749-24-034896.md) | not reported | [(1.35)](/filings/0001437749-25-016831.md) | [(0.88)](/filings/0001437749-25-032197.md) | [(0.61)](/filings/0001437749-25-034437.md) | not reported | [(0.59)](/filings/0001437749-26-017221.md) | [(0.40)](/filings/0001437749-25-032197.md) | [(0.24)](/filings/0001437749-25-034437.md) | not reported | [(0.21)](/filings/0001437749-26-017221.md) | [(0.13)](/filings/0001437749-26-027315.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: not reported
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $k | [1,835](/filings/0001437749-23-030938.md) | [1,103](/filings/0001437749-25-009397.md) | [949](/filings/0001437749-24-016611.md) | [1,421](/filings/0001437749-24-026310.md) | [4,930](/filings/0001437749-24-034896.md) | [2,371](/filings/0001437749-26-009587.md) | [949](/filings/0001437749-25-016831.md) | [980](/filings/0001437749-25-032197.md) | [5,287](/filings/0001437749-25-034437.md) | [2,496](/filings/0001437749-26-027315.md) | [951](/filings/0001437749-26-017221.md) | [4,117](/filings/0001437749-26-027315.md) |
| Current assets | $k | [2,116](/filings/0001437749-23-030938.md) | [1,461](/filings/0001437749-25-009397.md) | [1,259](/filings/0001437749-24-016611.md) | [1,573](/filings/0001437749-24-026310.md) | [5,056](/filings/0001437749-24-034896.md) | [2,622](/filings/0001437749-26-009587.md) | [1,173](/filings/0001437749-25-016831.md) | [1,199](/filings/0001437749-25-032197.md) | [5,365](/filings/0001437749-25-034437.md) | [2,732](/filings/0001437749-26-027315.md) | [1,140](/filings/0001437749-26-017221.md) | [4,298](/filings/0001437749-26-027315.md) |
| Total assets | $k | [3,747](/filings/0001437749-23-030938.md) | [2,987](/filings/0001437749-25-009397.md) | [2,679](/filings/0001437749-24-016611.md) | [2,890](/filings/0001437749-24-026310.md) | [6,267](/filings/0001437749-24-034896.md) | [3,724](/filings/0001437749-26-009587.md) | [2,166](/filings/0001437749-25-016831.md) | [2,089](/filings/0001437749-25-032197.md) | [6,148](/filings/0001437749-25-034437.md) | [3,413](/filings/0001437749-26-027315.md) | [1,712](/filings/0001437749-26-017221.md) | [4,755](/filings/0001437749-26-027315.md) |
| Current liabilities | $k | [3,330](/filings/0001437749-23-030938.md) | [3,608](/filings/0001437749-25-009397.md) | [4,071](/filings/0001437749-24-016611.md) | [4,071](/filings/0001437749-24-026310.md) | [2,840](/filings/0001437749-24-034896.md) | [2,321](/filings/0001437749-26-009587.md) | [3,234](/filings/0001437749-25-016831.md) | [3,642](/filings/0001437749-25-032197.md) | [3,310](/filings/0001437749-25-034437.md) | [2,432](/filings/0001437749-26-027315.md) | [2,778](/filings/0001437749-26-017221.md) | [2,055](/filings/0001437749-26-027315.md) |
| Total liabilities | $k | [4,407](/filings/0001437749-23-030938.md) | [4,590](/filings/0001437749-25-009397.md) | [4,954](/filings/0001437749-24-016611.md) | [4,851](/filings/0001437749-24-026310.md) | [3,514](/filings/0001437749-24-034896.md) | [2,887](/filings/0001437749-26-009587.md) | [3,686](/filings/0001437749-25-016831.md) | [3,975](/filings/0001437749-25-032197.md) | [3,521](/filings/0001437749-25-034437.md) | [2,518](/filings/0001437749-26-027315.md) | [2,778](/filings/0001437749-26-017221.md) | [2,055](/filings/0001437749-26-027315.md) |
| Shareholders' equity | $k | [(660)](/filings/0001437749-24-034896.md) | [(1,603)](/filings/0001437749-26-009587.md) | [(2,275)](/filings/0001437749-25-034437.md) | [(1,961)](/filings/0001437749-25-034437.md) | [2,753](/filings/0001437749-25-034437.md) | [837](/filings/0001437749-26-027315.md) | [(1,520)](/filings/0001437749-26-027315.md) | [(1,886)](/filings/0001437749-26-027315.md) | [2,627](/filings/0001437749-25-034437.md) | [895](/filings/0001437749-26-027315.md) | [(1,066)](/filings/0001437749-26-027315.md) | [2,700](/filings/0001437749-26-027315.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(2,412) d](/filings/0001437749-24-034896.md) | [(1,851) d](/filings/0001437749-25-009397.md) | [(1,530)](/filings/0001437749-25-016831.md) | [(1,312) d](/filings/0001437749-25-032197.md) | [(2,611) d](/filings/0001437749-25-034437.md) | [(2,433) d](/filings/0001437749-26-009587.md) | [(1,618)](/filings/0001437749-26-017221.md) | [(1,649) d](/filings/0001437749-26-027315.md) | [(1,672) d](/filings/0001437749-25-034437.md) | [(2,497) d](/filings/0001437749-26-009587.md) | [(1,659)](/filings/0001437749-26-017221.md) | [(1,735) d](/filings/0001437749-26-027315.md) |
| Capital expenditure | $k | [0.0 d](/filings/0001437749-24-034896.md) | [0.0 d](/filings/0001437749-25-009397.md) | [0.0](/filings/0001437749-24-016611.md) | [3.0 d](/filings/0001437749-25-032197.md) | [2.0 d](/filings/0001437749-25-034437.md) | [1.0 d](/filings/0001437749-26-009587.md) | [0.0](/filings/0001437749-26-017221.md) | [1.0 d](/filings/0001437749-26-027315.md) | [0.0 d](/filings/0001437749-25-034437.md) | [6.0 d](/filings/0001437749-26-009587.md) | [3.0](/filings/0001437749-26-017221.md) | [0.0 d](/filings/0001437749-26-027315.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2014 (2014-03-31) | Q2 FY2014 (2014-06-30) | Q3 FY2014 (2014-09-30) | Q1 FY2015 (2015-03-31) | Q2 FY2015 (2015-06-30) | Q3 FY2015 (2015-09-30) | Q1 FY2016 (2016-03-31) | Q2 FY2016 (2016-06-30) | Q3 FY2016 (2016-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [230](/filings/0001136261-15-000123.md) | [230](/filings/0001136261-15-000248.md) | [230](/filings/0001136261-15-000302.md) | [230](/filings/0001136261-16-000456.md) | [230](/filings/0001136261-16-000580.md) | [230](/filings/0001136261-16-000628.md) | [230](/filings/0001136261-16-000456.md) | [230](/filings/0001136261-16-000580.md) | [231](/filings/0001136261-16-000628.md) | [4.6](/filings/0001437749-26-017221.md) | [5.1](/filings/0001437749-26-027315.md) | [10.8](/filings/0001437749-26-017221.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 15,138,782 at 2026-08-11, from the cover of the [10-Q filed 2026-08-12](/filings/0001437749-26-027315.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:29 ET. No prices; not investment advice.